In recent years, there has been an increasing interest in developing dose finding methods incorporating both efficacy and toxicity outcomes. It is reasonable to assume that efficacy and toxicity are associated; therefore, we need to model their stochastic dependence. Copula functions are very useful tools to model different kinds of dependence with arbitrary marginal distributions. We consider a binary efficacy-toxicity response with logit marginal distributions. Since the dose which maximizes the probability of efficacy without toxicity (P-optimal dose) changes depending on different copula functions, we propose a criterion which is useful for choosing between the rival copula models but also protects patients against doses that are far away from the P-optimal dose. The performance of this compromise criterion (called PKL) is illustrated for different choices of the parameter values.
Deldossi, L., Osmetti, S. A., Tommasi, C., PKL-Optimality Criterion in Copula Models for Efficacy-Toxicity Response, in Kunert, J., Muller, C., Atkinson, A. (ed.), mODa11 - Advances in Model-Oriented Design and Analysis, Springer, Geneva, Switzerland 2016: <<CONTRIBUTIONS TO STATISTICS>>, 79- 86. 10.1007/978-3-319-31266-8_10 [http://hdl.handle.net/10807/86455]
PKL-Optimality Criterion in Copula Models for Efficacy-Toxicity Response
Deldossi, LauraPrimo
;Osmetti, Silvia AngelaSecondo
;
2016
Abstract
In recent years, there has been an increasing interest in developing dose finding methods incorporating both efficacy and toxicity outcomes. It is reasonable to assume that efficacy and toxicity are associated; therefore, we need to model their stochastic dependence. Copula functions are very useful tools to model different kinds of dependence with arbitrary marginal distributions. We consider a binary efficacy-toxicity response with logit marginal distributions. Since the dose which maximizes the probability of efficacy without toxicity (P-optimal dose) changes depending on different copula functions, we propose a criterion which is useful for choosing between the rival copula models but also protects patients against doses that are far away from the P-optimal dose. The performance of this compromise criterion (called PKL) is illustrated for different choices of the parameter values.File | Dimensione | Formato | |
---|---|---|---|
10_mODa 11.pdf
non disponibili
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Non specificato
Dimensione
220.96 kB
Formato
Unknown
|
220.96 kB | Unknown | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.